KalVista Phar­ma­ceu­ti­cals said Fri­day that the FDA pushed back its de­ci­sion on whether to ap­prove its on-de­mand oral drug for hered­i­tary an­gioede­ma, cit­ing “heavy work­load and lim­it­ed re­sources” at the agency...